Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Consolidated Net Income rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Consolidated Net Income is $2.0 million, which was up 3,069.35% from $62,000 recorded in Q2 2025.
  • Aytu Biopharma's Consolidated Net Income's 5-year high stood at $2.0 million during Q3 2025, with a 5-year trough of -$53.3 million in Q1 2022.
  • For the 3-year period, Aytu Biopharma's Consolidated Net Income averaged around -$956,545, with its median value being -$599,000 (2024).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 546.80% in 2021, then skyrocketed by 415.75% in 2025.
  • Aytu Biopharma's Consolidated Net Income (Quarterly) stood at -$11.5 million in 2021, then spiked by 42.04% to -$6.7 million in 2022, then spiked by 87.46% to -$839,000 in 2023, then skyrocketed by 114.66% to $123,000 in 2024, then skyrocketed by 415.75% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $62,000 for Q2 2025, and $54,000 during Q1 2025.